TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Triggers in Cardiac Surgery
Brief Summary: A high proportion of patients having cardiac surgery receive red cell transfusions. Yet, the investigators do not know whether transfusions are beneficial and they may be associated with harm. It is thus important to determine when a transfusion is required. The investigators will conduct a small pilot study at St. Michael's Hospital to address this issue. Patients having cardiac surgery will be allocated to one of two transfusion strategies with endpoints being compliance with the transfusion strategy and clinical outcome. The results of this study will be used to design a large definitive multicentered trial of these two transfusion strategies.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion with Red Blood Cells, Biological: 1 unit of donated red blood cells | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1 unit of donated red blood cells | Intervention Type: PROCEDURE; Name: Transfusion with Red Blood Cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 2
B: Arm Label: Haemoglobin (<6.0 mmol/l); Type: ACTIVE_COMPARATOR; Interventions: Other: Blood transfusion | Arm Label: Haemoglobin (< normal range); Type: EXPERIMENTAL; Interventions: Other: Blood transfusion | Intervention Type: OTHER; Name: Blood transfusion; Assigned to Arm(s): Haemoglobin (< normal range), Haemoglobin (<6.0 mmol/l)
C: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Intervention Type: BIOLOGICAL; Name: Red Blood Cell Transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive Transfusion Strategy
D: Arm Label: Low transfusion trigger; Type: ACTIVE_COMPARATOR; Interventions: Biological: red blood cell transfusion | Arm Label: High transfusion trigger; Type: ACTIVE_COMPARATOR; Interventions: Biological: red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: red blood cell transfusion; Assigned to Arm(s): High transfusion trigger, Low transfusion trigger

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Triggers in Cardiac Surgery
Brief Summary: A high proportion of patients having cardiac surgery receive red cell transfusions. Yet, the investigators do not know whether transfusions are beneficial and they may be associated with harm. It is thus important to determine when a transfusion is required. The investigators will conduct a small pilot study at St. Michael's Hospital to address this issue. Patients having cardiac surgery will be allocated to one of two transfusion strategies with endpoints being compliance with the transfusion strategy and clinical outcome. The results of this study will be used to design a large definitive multicentered trial of these two transfusion strategies.


Options:
A: Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Procedure: Restrictive transfusion, Biological: red blood transfusion | Arm Label: Liberal transfusion strategy; Type: EXPERIMENTAL; Interventions: Procedure: Liberal transfusion, Biological: red blood transfusion | Intervention Type: PROCEDURE; Name: Restrictive transfusion; Assigned to Arm(s): Restrictive transfusion strategy | Intervention Type: PROCEDURE; Name: Liberal transfusion; Assigned to Arm(s): Liberal transfusion strategy | Intervention Type: BIOLOGICAL; Name: red blood transfusion; Assigned to Arm(s): Liberal transfusion strategy, Restrictive transfusion strategy
B: Arm Label: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Type: ACTIVE_COMPARATOR; Interventions: Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Arm Label: Allowed drop in hemoglobin to 5.6-6.5 mmol/L; Type: EXPERIMENTAL; Interventions: Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 5.6-6.5 mmol/L
C: Arm Label: Low transfusion threshold; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: High transfusion threshold; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): High transfusion threshold, Low transfusion threshold
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion with Red Blood Cells, Biological: 1 unit of donated red blood cells | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1 unit of donated red blood cells | Intervention Type: PROCEDURE; Name: Transfusion with Red Blood Cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Triggers in Cardiac Surgery
Brief Summary: A high proportion of patients having cardiac surgery receive red cell transfusions. Yet, the investigators do not know whether transfusions are beneficial and they may be associated with harm. It is thus important to determine when a transfusion is required. The investigators will conduct a small pilot study at St. Michael's Hospital to address this issue. Patients having cardiac surgery will be allocated to one of two transfusion strategies with endpoints being compliance with the transfusion strategy and clinical outcome. The results of this study will be used to design a large definitive multicentered trial of these two transfusion strategies.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion with Red Blood Cells, Biological: 1 unit of donated red blood cells | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1 unit of donated red blood cells | Intervention Type: PROCEDURE; Name: Transfusion with Red Blood Cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 2
B: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
C: Arm Label: Shorter-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored <= 10 days | Arm Label: Longer-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored >= 21 days | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored <= 10 days; Assigned to Arm(s): Shorter-storage red blood cell units | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored >= 21 days; Assigned to Arm(s): Longer-storage red blood cell units
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Intervention Type: BIOLOGICAL; Name: Red Blood Cell Transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive Transfusion Strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Triggers in Cardiac Surgery
Brief Summary: A high proportion of patients having cardiac surgery receive red cell transfusions. Yet, the investigators do not know whether transfusions are beneficial and they may be associated with harm. It is thus important to determine when a transfusion is required. The investigators will conduct a small pilot study at St. Michael's Hospital to address this issue. Patients having cardiac surgery will be allocated to one of two transfusion strategies with endpoints being compliance with the transfusion strategy and clinical outcome. The results of this study will be used to design a large definitive multicentered trial of these two transfusion strategies.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion with Red Blood Cells, Biological: 1 unit of donated red blood cells | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1 unit of donated red blood cells | Intervention Type: PROCEDURE; Name: Transfusion with Red Blood Cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 2
B: Arm Label: Bair hugger forced air warming therapy; Type: EXPERIMENTAL; Interventions: Device: Bair Hugger forced air warming system | Arm Label: conventional warming care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bair Hugger forced air warming system; Assigned to Arm(s): Bair hugger forced air warming therapy
C: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
D: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison for Laparoscopically Assisted and Open Surgery for Advanced Rectal Cancer After Preoperative Chemoradiation- Randomized Prospective Trial
Brief Summary: The investigators designed the randomized prospective trial of comparing open and laparoscopic resection in locally advanced rectal cancer after preoperative chemoradiation in order to determine the oncologic and functional efficacy of laparoscopic rectal resection.


Options:
A: Arm Label: open rectal resection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: open rectal resection | Arm Label: laparoscopic rectal resection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic rectal resection | Intervention Type: PROCEDURE; Name: open rectal resection; Assigned to Arm(s): open rectal resection | Intervention Type: PROCEDURE; Name: laparoscopic rectal resection; Assigned to Arm(s): laparoscopic rectal resection
B: Arm Label: 1; Type: OTHER; Interventions: Procedure: surgery | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): 1
C: Intervention Type: PROCEDURE; Name: Laparoscopic surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Conventional surgery; Assigned to Arm(s): N/A
D: Arm Label: OPEN SURGERY; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RECTAL CANCER RESECTION | Arm Label: LAPAROSCOPIC SURGERY; Type: EXPERIMENTAL; Interventions: Procedure: RECTAL CANCER RESECTION | Intervention Type: PROCEDURE; Name: RECTAL CANCER RESECTION; Assigned to Arm(s): LAPAROSCOPIC SURGERY, OPEN SURGERY

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.
Brief Summary: The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine, Drug: cisplatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): A
B: Arm Label: 1. Gemcitabine monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gemcitabine | Arm Label: 2. Gemcitabine plus AGS-1C4D4; Type: EXPERIMENTAL; Interventions: Biological: AGS-1C4D4, Biological: Gemcitabine | Intervention Type: BIOLOGICAL; Name: AGS-1C4D4; Assigned to Arm(s): 2. Gemcitabine plus AGS-1C4D4 | Intervention Type: BIOLOGICAL; Name: Gemcitabine; Assigned to Arm(s): 1. Gemcitabine monotherapy, 2. Gemcitabine plus AGS-1C4D4
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: AG-013736, Drug: Gemcitabine | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: placebo | Intervention Type: DRUG; Name: AG-013736; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Arm Label: Erlotinib; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Erlotinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Percutaneous Transluminal Balloon Angioplasty (PTA) and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia
Brief Summary: The purpose of this study is to investigate the performance of paclitaxel-coated balloon expandable stainless steel coronary stent for the treatment of infrapopliteal stenoses and occlusions in patients with critical limb ischemia compared to percutaneous transluminal balloon angioplasty (PTA).


Options:
A: Arm Label: Laser atherectomy and PTA; Type: EXPERIMENTAL; Interventions: Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters | Arm Label: Balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Balloon angioplasty | Intervention Type: DEVICE; Name: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters; Assigned to Arm(s): Laser atherectomy and PTA | Intervention Type: PROCEDURE; Name: Balloon angioplasty; Assigned to Arm(s): Balloon angioplasty
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: PTA with placement of paclitaxel-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA | Intervention Type: DEVICE; Name: PTA with placement of paclitaxel-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Percutaneous Transluminal Angioplasty | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: LifeStent NT™ Self-Expanding Peripheral Stent | Intervention Type: OTHER; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: LifeStent NT™ Self-Expanding Peripheral Stent; Assigned to Arm(s): 2
D: Arm Label: REA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote endarterectomy of the superficial femoral artery | Arm Label: Bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Suprageniculate femoropopliteal bypass | Intervention Type: PROCEDURE; Name: Remote endarterectomy of the superficial femoral artery; Assigned to Arm(s): REA | Intervention Type: PROCEDURE; Name: Suprageniculate femoropopliteal bypass; Assigned to Arm(s): Bypass

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Percutaneous Transluminal Balloon Angioplasty (PTA) and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia
Brief Summary: The purpose of this study is to investigate the performance of paclitaxel-coated balloon expandable stainless steel coronary stent for the treatment of infrapopliteal stenoses and occlusions in patients with critical limb ischemia compared to percutaneous transluminal balloon angioplasty (PTA).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: PTA with placement of paclitaxel-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA | Intervention Type: DEVICE; Name: PTA with placement of paclitaxel-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Implantation of YUKON Sirolimus-eluting Stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Implantation of YUKON Stent (uncoated) | Intervention Type: DEVICE; Name: Implantation of YUKON Sirolimus-eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Implantation of YUKON Stent (uncoated); Assigned to Arm(s): 2
C: Arm Label: Astron Pulsar Stent; Type: EXPERIMENTAL; Interventions: Device: Astron Pulsar Stent | Arm Label: PTA alone; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA alone | Intervention Type: DEVICE; Name: Astron Pulsar Stent; Assigned to Arm(s): Astron Pulsar Stent | Intervention Type: DEVICE; Name: PTA alone; Assigned to Arm(s): PTA alone
D: Arm Label: Drug Coated Balloon (DCB) Arm; Type: EXPERIMENTAL; Interventions: Procedure: Paclitaxel coated balloon angioplasty. | Arm Label: Drug Eluting Stents (DES) Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infrapopliteal Primary Drug Eluting Stenting | Intervention Type: PROCEDURE; Name: Paclitaxel coated balloon angioplasty.; Assigned to Arm(s): Drug Coated Balloon (DCB) Arm | Intervention Type: PROCEDURE; Name: Infrapopliteal Primary Drug Eluting Stenting; Assigned to Arm(s): Drug Eluting Stents (DES) Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria
Brief Summary: Diabetes is associated with dyslipidaemia leading to generalized atherosclerosis, cardiovascular disease (CVD) and nephropathy. Osteoprotegerin (OPG), a glycoprotein involved in bone homeostasis, has been implicated in the pathogenesis leading up vessel calcification. Furthermore, CVD in diabetics is associated with increased levels of OPG.

Aim: To investigate whether low dose simvastatin treatment (10-20 mg/day) reduces circulating levels of OPG as well as adhesion molecules (VCAM-1; vascular cell adhesion molecule-1, ICAM; intercellular cell adhesion molecule).


Options:
A: Intervention Type: DRUG; Name: Statin (simvastatin); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Simvastatin 20mg plus Ezetimibe 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin 20 mg, Drug: Ezetimibe 10mg | Arm Label: Simvastatin 20mg; Type: OTHER; Interventions: Drug: Simvastatin 20 mg | Intervention Type: DRUG; Name: Simvastatin 20 mg; Assigned to Arm(s): Simvastatin 20mg, Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Ezetimibe 10mg; Assigned to Arm(s): Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe/simvastatin, Drug: Placebo for simvastatin 40 mg | Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: Placebo for simvastatin 40 mg, Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo for simvastatin 40 mg; Assigned to Arm(s): ezetimibe/simvastatin, simvastatin | Intervention Type: DRUG; Name: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination; Assigned to Arm(s): simvastatin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone Infusion in Community-acquired Pneumonia
Brief Summary: The purpose of this study is to determine whether dexamethasone reduces the length of hospital stay in patient with a community-acquired pneumonia.


Options:
A: Arm Label: Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo, Prednisone
B: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone Infusion in Community-acquired Pneumonia
Brief Summary: The purpose of this study is to determine whether dexamethasone reduces the length of hospital stay in patient with a community-acquired pneumonia.


Options:
A: Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 1, 2
C: Arm Label: H; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone | Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): H | Intervention Type: DRUG; Name: NaCl; Assigned to Arm(s): P
D: Intervention Type: DRUG; Name: hydrocortisone 200 mg/day; Assigned to Arm(s): N/A

Answer: B